Fas and Fas-L expression in Huntington's disease and Parkinson's disease

Neuropathology and Applied Neurobiology

Volumn 26, Issue 5, 2000, Pages 424-433

  Ferrer, I ^a   Blanco, R ^a   Cutillas, B ^b   Ambrosio, S ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cell death; Fas; Fas L; Huntington's disease; Parkinson's disease

Indexed keywords

FAS ANTIGEN; FAS LIGAND;

AGED; ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CELL DEATH; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GENETIC DISORDER; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; MALE; NEUROLOGIC DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

AGED; ANTIGENS, CD95; BLOTTING, WESTERN; BRAIN; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FAS LIGAND PROTEIN; FEMALE; HUMANS; HUNTINGTON DISEASE; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; PARKINSON DISEASE;

EID: 0033775865     PISSN: 03051846     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2990.2000.00267.x     Document Type: Article

References (54)

1. Fas expression on human fetal astrocytes without susceptibility to fas-mediated cytotoxicity
2. FasL (CD95L, Apo1L) is expressed in the normal rat and human brain: Evidence for the existence of an immunological brain barrier
3. The Fas-based mechanism of lymphocytotoxicity
4. Multiple sclerosis: Oligodendrocytes display cell death-related molecules in situ but do not undergo apoptosis
5. Parkinson's disease
6. Fas/Apo-1 (CD95) receptor lacking the intracytoplasmic signaling domain protects tumor cells from Fas-mediated apoptosis
7. Protection from Fas-mediated apoptosis by a soluble form of Fas molecule
8. Portrait of an executioner: The molecular mechanism of Fas/APO-1-induced apoptosis
9. Neuro-degeneration induced by MoMuLV-ts1 and increased expression of Fas and TNF-α in the central nervous system
10. Fas ligand and Fas are expressed constitutively in human astrocytes and the expression increases with IL-1, IL-6, TNF-α, or IFN-γ
11. P53- and CD95-associated apoptosis in neurodegenerative diseases
12. Correlates of p53- and Fas (CD95)-mediated apoptosis in Alzheimer's disease
13. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in multiple sclerosis brain
14. In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes
15. Multiple sclerosis: Fas signaling in oligodendrocyte cell death
16. The Fas pathway in apoptosis
17. Nuclear DNA fragmentation in Creutzfeldt-Jakob disease: Does a mere positive in situ nuclear end-labeling indicate apoptosis
18. Neuropathology of Parkinsons disease
19. Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
20. Regulation of Fas-mediated apoptosis
21. Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors
22. α-Synuclein in Lewy body disease. Alzheimer's disease
23. Co-expression of Fas and Fas ligand in malignant glial tumors cell lines
24. Is there apoptosis in Lewy body disease?
25. On the question of apoptosis in the parkinsonian substantia nigra
26. Signalling by CD95 and TNF receptors. Not only life death
27. CD95 ligand (Fas-L/APO-1L) and tumor necrosis factor-related apoptosis-inducing ligand mediate ischemia-induced apoptosis in neurons
28. Localization of Fas antigen mRNA in post-ischemic murine forebrain by in situ hybridization
29. Histochemical detection of apoptosis in Parkinson's disease
30. The soluble form of Fas molecule is elevated in parkinsonian brain tissue
31. Apoptosis mediated by the Fas system
32. Fas antigen expression in brains of patients with Alzheimer-type dementia
33. Mechanisms of CD95 (APO-1/Fas)-mediated apoptosis
34. Evidence of apoptotic cell death in Huntington's disease and excitotoxic animal models
35. Differential loss of striatal projection neurons in Huntington's disease
36. Huntington's disease and DRPLA
37. CD95 (Fas/Apo-1) as a receptor governing asrtrocytic apoptotic or inflammatory responses: A key role in brain inflammation?
38. Fas ligand expression by astrocytoma in vivo: Maintaining immune privilege in the brain?
39. Delayed selective motor neuron death by fas antigen induction after spinal cord ischemia in rabbits
40. Apoptosis-associated proteins p53 and APO-1/Fas (CD95) in brains of adult patients with Down syndrome
41. The role of Fas and related death receptors in autoimmune and other disease states
42. Alzheimer disease: DNA fragmentation indicates increased nuclear vulnerability, but not apoptosis
43. Preferential expression of Fas/APO1 (CD95) and apoptotic cell death in perinecrotic cells of glioblastoma multiforme
44. Expression of Fas/APO-1 during the progression of astrocytoma
45. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
46. DNA end-labeling (TUNEL) in Huntington's disease and other neuropathological conditions
47. Necrogenesis and Fas/APO-1 (CD95) expression in primary (de novo) and secondary glioblastomas
48. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigra neurons
49. Inhibition of Fas death signals by FLIPs
50. Huntington's disease
51. Tumor expression of Fas ligand (CD95L) and the consequences
52. Tumor necrosis factor receptor and Fas signaling mechanisms
53. CD95 ligand: Lethal weapon against malignant glioma?
54. Cell death and apoptosis regulating proteins in Parkinson's disease. A cautionary note